Navigation Links
AMEX Accepts Lorus' Plan to Meet AMEX's Continued Listing Standards
Date:5/6/2008

TORONTO, May 6 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus" or the "Company") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, has received a notice from the American Stock Exchange ("AMEX") indicating that Amex has accepted Lorus' plan of compliance and granted the Company an extension until no later than August 13, 2009 to regain compliance with the AMEX's continued listing standards.

As previously disclosed, on February 19, 2008, the Company received notice from the AMEX staff indicating that the Company was not in compliance with the $6 million stockholder's equity threshold required for continued listing under AMEX Company Guide Section 1003(a)(iii). The Company was afforded the opportunity to submit a plan of compliance to the AMEX and on March 11, 2008 presented its plan to the AMEX. On April 30, 2008 AMEX notified the Company that it accepted the Company's plan of compliance and granted the Company an extension until August 13, 2009 to regain compliance with the continued listing standards.

The Company will be subject to periodic review by the AMEX during the extension period. Continued listing on AMEX is dependent upon making progress consistent with the plan or in regaining compliance with the continued listing standards by the end of the extension period.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock E
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mike Huckabee Accepts Values Voter Presidential Debate
2. ev3 Inc. Accepts Resignation of Dr. John Simpson
3. Lieutenant Governor Catherine Baker Knoll Accepts Women in Government Presidential Leadership Award
4. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
5. Governor Rendell Accepts National Health Care Reform Pioneer Award
6. American Stock Exchange Accepts Encisions Plan to Regain Compliance
7. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
8. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
9. Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
(Date:9/2/2014)... 2014 Smile Squared, a well-known Buy ... to include a US-made toothbrush. For every toothbrush purchased, ... , “Smile Squared was created by my wife and ... said Eric Cope, President of Smile Squared. “There, we ... problems. But many of the same children didn't own ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: Digoxin may increase ... (AF) by approximately 20%, according to results from the ... Dr Manesh Patel, director of interventional cardiology and catheterisation ... Carolina, US. The findings suggest that caution may be ... further studies are needed to confirm the observations. , ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: The fact that ... has been confirmed by data from the ROPAC registry ... Congress Hot Line session by Professor Jolien W. Roos-Hesselink, ... committee. The registry found that 1.4% of pregnant women ... their baby during pregnancy. , The Registry Of Pregnancy ...
Breaking Medicine News(10 mins):Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3
... 2009 The first results of the first European survey ... at the 6th congress of the European Federation of Chapters ... , Previous surveys have looked at the overall management of ... study to look in detail at Breakthrough Cancer Pain (BTCP) ...
... ... relationship to offer comprehensive staffing, scheduling, and credentialing software to nurse staffing ... no additional charge. , ... Nashville, TN (Vocus) September 11, 2009 -- BlueSky Synergy, LLC (BlueSky) and People ...
... ... Yum-Yum D3 Gummies, Yum-Yum GOS Syrup (prebiotic fiber syrup), and Yum-Yum Zymes at the ... and Exhibition Center in Boston, MA, September 24-26, 2009. , ... Los Angeles, CA (PRWEB) September 11, 2009 ...
... ... dental group practice in central North Carolina, today announced the addition of Dr. Brian Cahill ... ... pleased to announce that Dr. Brian Cahill has joined their cosmetic and family dental practice. ...
... , , NEW YORK, Sept. 10 ... The Mount Sinai Medical Center describe the Community Diabetes and ... program which was designed specifically for people from the vulnerable Latino ... Twenty-five patients from The Mount Sinai Medical Center were randomly selected ...
... speed immunity, experts say , THURSDAY, Sept. 10 (HealthDay ... vaccine conducted in Australia and Britain show that a ... virus within about 10 days. , That,s a potentially ... would be needed to provide full immunity to the ...
Cached Medicine News:Health News:First results from major European patient survey show devastating impact of living with breakthrough cancer pain 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 2Health News:BlueSky Synergy, a Division of Amistaff Healthcare Technology, and People 2.0 Global Partner to Provide Complimentary Staffing Software to Participating Companies 3Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 2Health News:Jarrow Formulas, Inc. to Unveil Children's Natural Health Products at Upcoming Natural Products Expo East Show in Boston 3Health News:Dr. Brian Cahill Joins Research Triangle Dental 2Health News:Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Program's Graduation Ceremony on September 16th 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 2Health News:One Dose of Swine Flu Vaccine Offers Protection: Studies 3
(Date:9/2/2014)... , Sept. 2, 2014 Redspin, Inc., ... penetration testing services, today released an IT security advisory ... "Today,s healthcare CEOs are presiding over the most ... Daniel W. Berger , Redspin,s President and CEO. ... and their Boards of Directors understand why they need ...
(Date:9/2/2014)... ATLANTA , Sept. 2, 2014  For over a ... show no link between vaccines and autism. But at least ... In a statement , William Thompson ... significant information" linking the MMR vaccine to an increased risk ... of the same data suggests that African American males ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 /PRNewswire-iReach/ -- ... just recognized as one of the fastest growing ... past few years, the company has undergone significant ... research, late phase global clinical development, anti-viral and ... 2 years, WCCT Global has successfully participated in ...
Breaking Medicine Technology:CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2
... SweetSpot Diabetes Care, Inc. has registered their ... Device Data System (MDDS) with the FDA the Company announced ... Sessions meeting in San Diego, CA. With the ... of data from patient diabetes devices to research tools and ...
... Golden Meditech Holdings Limited ("Golden Meditech" or the "Group," ... that the Group has accumulated 754,791 ordinary shares in its ... the open market between December 2010 and March 2011. As ... the issued share capital of CCBC. CCBC is ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2
... Atlantech's new tibial guide is designed for ... to choose between "point" or "elbow" aimers ... for creation of the tibial tunnel. The ... design features and the reproducibility and accuracy ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Hand surgery basic instrument set...
Hand surgery basic instrument set with round handled instruments...
Medicine Products: